| Drug interactions: principles and practice BD Snyder, TM Polasek, MP Doogue | 119 | 2012 |
| The ABCD of clinical pharmacokinetics MP Doogue, TM Polasek Therapeutic advances in drug safety 4 (1), 5-7, 2013 | 107 | 2013 |
| Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro TM Polasek, DJ Elliot, BC Lewis, JO Miners Journal of Pharmacology and Experimental Therapeutics 311 (3), 996-1007, 2004 | 106 | 2004 |
| Perpetrators of pharmacokinetic drug–drug interactions arising from altered cytochrome P450 activity: a criteria‐based assessment TM Polasek, FPY Lin, JO Miners, MP Doogue British journal of clinical pharmacology 71 (5), 727-736, 2011 | 98 | 2011 |
| Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate TM Polasek, JO Miners European journal of clinical pharmacology 62, 203-208, 2006 | 95 | 2006 |
| Drug dosing in renal disease MP Doogue, TM Polasek The Clinical Biochemist Reviews 32 (2), 69, 2011 | 90 | 2011 |
| An evaluation of potential mechanism‐based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid TM Polasek, DJ Elliot, AA Somogyi, EMJ Gillam, BC Lewis, JO Miners British journal of clinical pharmacology 61 (5), 570-584, 2006 | 81 | 2006 |
| Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins KJ Barnes, A Rowland, TM Polasek, JO Miners European journal of clinical pharmacology 70, 1097-1106, 2014 | 76 | 2014 |
| In vitro approaches to investigate mechanism-based inactivation of CYP enzymes TM Polasek, JO Miners Expert Opinion on Drug Metabolism & Toxicology 3 (3), 321-329, 2007 | 69 | 2007 |
| Potential drug–drug interactions with direct oral anticoagulants in elderly hospitalized patients HL Forbes, TM Polasek Therapeutic advances in drug safety 8 (10), 319-328, 2017 | 67 | 2017 |
| Model-informed precision dosing: background, requirements, validation, implementation, and forward trajectory of individualizing drug therapy AS Darwich, TM Polasek, JK Aronson, K Ogungbenro, DFB Wright, ... Annual Review of Pharmacology and Toxicology 61, 225-245, 2021 | 62 | 2021 |
| Precision dosing in clinical medicine: present and future TM Polasek, S Shakib, A Rostami-Hodjegan Expert review of clinical pharmacology 11 (8), 743-746, 2018 | 62 | 2018 |
| Predicted metabolic drug clearance with increasing adult age TM Polasek, F Patel, BP Jensen, MJ Sorich, MD Wiese, MP Doogue British journal of clinical pharmacology 75 (4), 1019-1028, 2013 | 56 | 2013 |
| Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation TM Polasek, GT Tucker, MJ Sorich, MD Wiese, T Mohan, ... British journal of clinical pharmacology 84 (3), 462-476, 2018 | 54 | 2018 |
| In vitro–in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6α-hydroxylation: Effects of albumin on in vitro kinetic parameters and assessment of interindividual variability … N Wattanachai, TM Polasek, TM Heath, V Uchaipichat, W Tassaneeyakul, ... European journal of clinical pharmacology 67, 815-824, 2011 | 50 | 2011 |
| Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis MD Wiese, A Rowland, TM Polasek, MJ Sorich, C O'Doherty Expert Opinion on Drug Metabolism & Toxicology 9 (8), 1025-1035, 2013 | 46 | 2013 |
| In vitro characterization of the human liver microsomal kinetics and reaction phenotyping of olanzapine metabolism P Korprasertthaworn, TM Polasek, MJ Sorich, AJ McLachlan, JO Miners, ... Drug Metabolism and Disposition 43 (11), 1806-1814, 2015 | 43 | 2015 |
| Time‐dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants TM Polasek, JO Miners British journal of clinical pharmacology 65 (1), 87-97, 2008 | 42 | 2008 |
| Model‐informed drug development for anti‐infectives: state of the art and future CR Rayner, PF Smith, D Andes, K Andrews, H Derendorf, LE Friberg, ... Clinical Pharmacology & Therapeutics 109 (4), 867-891, 2021 | 34 | 2021 |
| What does it take to make model-informed precision dosing common practice? Report from the 1st Asian symposium on precision dosing TM Polasek, A Rostami-Hodjegan, DS Yim, M Jamei, H Lee, H Kimko, ... The AAPS journal 21, 1-9, 2019 | 31 | 2019 |
